Metformin for Metabolic Health & Longevity — Aging
First-line biguanide for type 2 diabetes with emerging evidence for anti-aging and cancer prevention benefits (TAME trial).
Overview
Metformin is a biguanide drug that has been the cornerstone of type 2 diabetes management for over 60 years, with the most extensive safety record of any antidiabetic medication. Its primary mechanism involves activation of AMP-activated protein kinase (AMPK) through mild inhibition of mitochondrial complex I, reducing hepatic glucose production and improving insulin sensitivity. Beyond glycemic control, epidemiological studies in diabetic populations have shown metformin users have lower all-cause mortality, reduced cancer incidence, and decreased cardiovascular events compared to matched controls — even when compared to non-diabetic individuals. These observations led to the landmark TAME (Targeting Aging with Metformin) trial, the first FDA-approved clinical trial to test a drug specifically for aging as an indication. Metformin's anti-aging mechanisms include AMPK activation, mTOR pathway modulation, reduced oxidative stress, anti-inflammatory effects, and potential senolytic properties. In the longevity community, healthy non-diabetic individuals are using metformin 500-1000 mg daily as a geroprotective agent, though the evidence for benefit in metabolically healthy individuals is contested. Notably, metformin may blunt exercise-induced mitochondrial adaptations, which is a concern for those combining it with an exercise regimen.
Indications
- FDA-approved: Type 2 diabetes mellitus (first-line therapy)
- Off-label: Prediabetes / diabetes prevention
- Off-label: Polycystic ovary syndrome (PCOS)
- Off-label: Anti-aging / longevity (TAME trial population)
- Off-label: Gestational diabetes prevention
- Investigational: Cancer prevention and adjuvant therapy
Mechanism of Action
Mildly inhibits mitochondrial respiratory chain complex I, increasing AMP:ATP ratio and activating AMPK
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Metformin ER (extended-release) | 500 mg | Once daily with dinner | Starting dose for longevity use; ER reduces GI effects |
| Metformin ER | 1000 mg | Once daily with dinner | Maintenance longevity dose; also common T2DM dose |
| Metformin IR (immediate-release) | 500 mg | Twice daily with meals | Standard T2DM starting dose |
| Metformin IR | 850-1000 mg | Twice daily | Maximum efficacy dose for T2DM — 2000 mg/day |
Evidence Grade
GRADE A
Safety & Contraindications
- GI side effects very common: nausea, diarrhea, abdominal discomfort, metallic taste — especially at initiation
- Extended-release (ER) formulation reduces GI side effects significantly
- Lactic acidosis risk (rare but serious, primarily in renal impairment)
- Vitamin B12 deficiency with long-term use (10-30% of users) — monitor annually
- Contraindicated in eGFR < 30 mL/min; use caution eGFR 30-45 mL/min
- Hold 48 hours before and after iodinated contrast procedures
- May blunt exercise-induced mitochondrial adaptations (important for athletes/fitness-focused users)